Roles
- Professor
- Director, Infectious Diseases Research Unit
-
Biography
Dr. Alcaide is an Infectious Diseases physician scientist, and faculty member of the University of Miami for over 15 years. She holds additional secondary appointments in the Department of Obstetrics, Gynecology, and Reproductive Sciences and the Department of Public Health. Throughout her career as a clinician and researcher, Dr. Alcaide has provided scientific and administrative oversight to numerous multidisciplinary research studies focused on HIV and other emerging infections in the US and other international settings. Dr. Alcaide has served as a principal investigator on large number of NIH-funded studies. Her research portfolio in 2022 was over $10 million, and she is among the top funded NIH scholars. She has provided exceptional leadership as Director of Clinical Research since 2020 at the Miller School of Medicine. She is also the director of the Miami CTSI and the Miami Center for AIDS Research mentoring programs, and plays a critical role in mentoring junior investigators, with a focus on women and underrepresented groups. As the Vice Provost for Research and Scholarship, she oversees the University’s burgeoning research portfolio under the Office of the Vice Provost for Research Administration, and leads the development of University wide scholarship initiatives. -
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Honors & Awards
-
Teaching Interests
HIV/AIDS and Infectious Diseases
Mentoring -
Research Interests
HIV
SARS-CoV-2
Sexually Transmitted Infections
Bacterial Vaginosis
Women's health
HIV and pregnancy -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.Professional Activities
Articles & News
2026 Faculty Awards Celebrate Excellence Across the Miller School of Medicine and UHealth
How Miller School of Medicine Researchers are Advancing HIV and Healthy Aging Research
Spain’s Consul Visits University of Miami Miller School of Medicine, Spotlighting Global Impact of Research
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 2 clinical trials.
-
This is a Phase 1b, randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics, and pharmacodynamics of multiple doses of ABBV-181 in ART-suppressed HIV-1 infected adult subjects, with a planned intensively-monitored ART interruption following the last dose of study drug.The main objectives of this study are to evaluate the safety and tolerability of multiple doses of ABBV-181 versus placebo in HIV-1 infected adult subjects and to evaluate the pharmacokinetics (PK) and peripheral PD-1 receptor saturation (RS) of multiple doses of ABBV-181 in HIV-1 infected adult subjectsThis study will be divided in two stages (Stage I and Stage II). Theperiods for each stage are as follows:Study Drug Dosing PeriodPost-Treatment Period (ART Interruption/ART Restart)All study site personnel, including investigators, study coordinators, and study subjects, will remain blinded to the treatment throughout the course of the study, except for the study drug preparation designee (including support personnel) or pharmacist.
- Principal Investigator: Maria Alcaide
- Study Phase: Phase I
- Enrollment Status: Closed
-
The MACS/WIHS Combined Cohort Study is a multicenter longitudinal study of persons living with and at risk for HIV funded by the National Institutes of Health to investigate the progression of HIV disease in men and women. Most of the approximately 4,500 participants of each cohort will be asked to enroll in the MWCCS. Those who enroll will be followed with an annual, protocol-driven visit and intermediate in-person and phone contacts, including substantial outcomes ascertainment. Further, we will recruit approximately 1500 new participants (including persons without HIV) to support our scientific aims, emphasizing black and Hispanic MSM and individuals in the southern U.S. PRIMARY AIMS:Cardiovascular Aims to identify novel behavioral and HIV-related risk factors associated with: a) fatal and incident hospitalized nonfatal CVD events; and b) development and progression of subclinical cardiac structural and functional abnormalities. Pulmonary/Sleep Aims to identify novel risk factors, biomarkers, and the influence of HIV infection on lung function trajectory, pulmonary exacerbations, respiratory symptoms, sleep quality, and habitual sleep duration.Neurocognitive Aims to describe the pattern and profile of cognitive impairment and their associated risk factors and risk modifiers.Aging Aims to investigate:Longitudinal changes in physical function and factors influencing these changes.The incidence of geriatric conditions, including multimorbidity, and factors influencing these conditions.Molecular and biochemical markers of aging.The biology of healthy or successful aging.Cancer Aims to determine a) the incidence of and risk factors associated with AIDS and non-AIDS-related malignancies; and b) factors (e.g., psychosocial, behavioral, cancer treatment, HIV-related, and comorbidities) associated with cancer survivorship.Psychosocial Aims to examine: a) trajectories of vulnerabilities and resiliencies and their relationship to HIV outcomes and comorbidities; andb) mechanisms by which psychosocial/behavioral and structural predictors affect health outcomes.Health Disparities Aims: By expanding enrollment to men in the Southeast and PLWH elsewhere who are representative of the U.S. epidemic, we will: a) evaluate the effect of personal (e.g., race, sex, education, income) and neighborhood-level characteristics (e.g., census tract-level poverty, county-level income inequality) on achieving prevention and treatment targets for comorbidity outcomes among people with and at higher risk for HIV infection; and b) refine methods for estimating differences in achieving health guideline targets to reduce the incidence of MI and stroke, lung cancer, and all-cause and cause-specific mortality.COVID-19 Aims to understand the impact of the coronavirus pandemic among U.S. men and women with or at-risk for HIV infection.SECONDARY AIMS:They aim to serve as a reliable, valid, and standardized platform for collaborative and independently funded research with investigators within the MWCCS and external investigators by:Continuing the collection of fresh specimens (blood, urine, oral, stool, cervicovaginal lavage, hair, and tissue for tumor and reservoir studies) and measuring clinical, immunologic, and virologic markers.Expanding assessments of comorbid conditions and adjudicated clinical outcomes (e.g., cardiovascular, renal, liver disease, cancer, and death).Developing a MACS-WIHS omics platform (e.g., genome, microbiome).The aim is to foster the development of early-career investigators from pre-doctoral students to post-doctoral fellows and early career faculty interested in HIV research and engage early established investigators not currently conducting HIV-related research in innovative HIV-related studies leveraging the platform of the MWCCS.Subject Selection and Withdrawal All MACS and WIHS participants currently under follow-up are eligible to enroll in MWCCS. In addition,
- Principal Investigator: Maria Alcaide
- Study Phase: N/A
- Enrollment Status: Open
